KRAS and non-small cell lung carcinoma: As a dual‐target inhibitor, embelin decreases proliferation, induces cellular senescence, reverses epithelial mesenchymal transformation (EMT), overcomes negative feedback from the MAPK signaling pathway, induces apoptosis, and thus reduces the malignant phenotype of KRAS‐mutant NSCLC, both in vivo and in vitro.